X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Aventis Pharma with Sterling Biotech - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SANOFI INDIA vs STERLING BIOTECH - Comparison Results

SANOFI INDIA    Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

STERLING BIOTECH 
   Change

Sterling Biotech primarily produces and distributes pharmaceutical grade gelatine globally. The company currently has a 7.5% share of the global market for pharmaceutical and nutraceutical gelatines. It has more than 70% market share in India. Sterli... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SANOFI INDIA STERLING BIOTECH SANOFI INDIA/
STERLING BIOTECH
 
P/E (TTM) x 33.0 -1.9 - View Chart
P/BV x 6.3 0.1 8,620.1% View Chart
Dividend Yield % 1.4 0.0 -  

Financials

 SANOFI INDIA   STERLING BIOTECH
EQUITY SHARE DATA
    SANOFI INDIA
Dec-16
STERLING BIOTECH
Dec-13
SANOFI INDIA/
STERLING BIOTECH
5-Yr Chart
Click to enlarge
High Rs4,56011 43,428.6%   
Low Rs4,4003 129,411.8%   
Sales per share (Unadj.) Rs1,028.526.8 3,836.7%  
Earnings per share (Unadj.) Rs129.0-15.0 -862.2%  
Cash flow per share (Unadj.) Rs186.0-5.5 -3,404.4%  
Dividends per share (Unadj.) Rs68.000-  
Dividend yield (eoy) %1.50-  
Book value per share (Unadj.) Rs753.654.9 1,373.2%  
Shares outstanding (eoy) m23.03267.87 8.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.40.3 1,680.1%   
Avg P/E ratio x34.7-0.5 -7,476.0%  
P/CF ratio (eoy) x24.1-1.3 -1,893.4%  
Price / Book Value ratio x5.90.1 4,694.3%  
Dividend payout %52.70-   
Avg Mkt Cap Rs m103,1741,862 5,542.0%   
No. of employees `0003.61.4 267.6%   
Total wages/salary Rs m3,592547 656.9%   
Avg. sales/employee Rs Th6,537.75,303.3 123.3%   
Avg. wages/employee Rs Th991.4403.8 245.5%   
Avg. net profit/employee Rs Th819.8-2,959.0 -27.7%   
INCOME DATA
Net Sales Rs m23,6867,181 329.9%  
Other income Rs m70843 1,662.0%   
Total revenues Rs m24,3947,223 337.7%   
Gross profit Rs m5,281947 557.7%  
Depreciation Rs m1,3132,543 51.6%   
Interest Rs m154,377 0.3%   
Profit before tax Rs m4,661-5,931 -78.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,691-1,924 -87.9%   
Profit after tax Rs m2,970-4,007 -74.1%  
Gross profit margin %22.313.2 169.1%  
Effective tax rate %36.332.4 111.8%   
Net profit margin %12.5-55.8 -22.5%  
BALANCE SHEET DATA
Current assets Rs m15,67314,335 109.3%   
Current liabilities Rs m6,67849,809 13.4%   
Net working cap to sales %38.0-494.0 -7.7%  
Current ratio x2.30.3 815.5%  
Inventory Days Days76403 18.8%  
Debtors Days Days22171 13.1%  
Net fixed assets Rs m8,09855,432 14.6%   
Share capital Rs m230268 86.0%   
"Free" reserves Rs m17,08813,935 122.6%   
Net worth Rs m17,35614,701 118.1%   
Long term debt Rs m09,478 0.0%   
Total assets Rs m25,40073,988 34.3%  
Interest coverage x311.7-0.4 -87,821.8%   
Debt to equity ratio x00.6 0.0%  
Sales to assets ratio x0.90.1 960.8%   
Return on assets %11.80.5 2,346.2%  
Return on equity %17.1-27.3 -62.8%  
Return on capital %26.9-6.4 -419.3%  
Exports to sales %24.525.9 94.6%   
Imports to sales %28.00.2 16,467.7%   
Exports (fob) Rs m5,8011,860 311.9%   
Imports (cif) Rs m6,62712 54,319.7%   
Fx inflow Rs m7,1451,860 384.2%   
Fx outflow Rs m6,84625 27,505.0%   
Net fx Rs m2991,835 16.3%   
CASH FLOW
From Operations Rs m3,2261,719 187.7%  
From Investments Rs m-1,555-3,148 49.4%  
From Financial Activity Rs m-1,8181,426 -127.5%  
Net Cashflow Rs m-147-3 4,323.5%  

Share Holding

Indian Promoters % 0.0 33.9 -  
Foreign collaborators % 60.4 0.0 -  
Indian inst/Mut Fund % 14.4 0.0 -  
FIIs % 14.6 9.9 147.5%  
ADR/GDR % 0.0 16.9 -  
Free float % 10.5 39.3 26.7%  
Shareholders   15,184 21,482 70.7%  
Pledged promoter(s) holding % 0.0 55.9 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SANOFI INDIA With:   DIVIS LABORATORIES  ELDER PHARMA  ALEMBIC LTD  PANACEA BIOTECH  CADILA HEALTHCARE  

Compare SANOFI INDIA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades in Green; IT Stocks Top Gainers(01:30 pm)

After opening the day marginally higher, share markets in India continued the momentum and are presently trading in green. Sectoral indices are trading on a mixed note, with stocks in the IT sector.

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Nirvana denied: Has Value Failed?(The Honest Truth)

Jan 13, 2018

Should investors choose growth over value this year?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SANOFI INDIA SHARE PRICE


Jan 22, 2018 03:33 PM

TRACK SANOFI INDIA

  • Track your investment in SANOFI INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SANOFI INDIA 5-YR ANALYSIS

COMPARE SANOFI INDIA WITH

MARKET STATS